12
Participants
Start Date
August 13, 2019
Primary Completion Date
October 31, 2019
Study Completion Date
October 31, 2019
PF-06865571 400 mg Immediate Release (IR) in Fed State
400 mg IR dose in fed state
PF-06865571 50 mg Modified Release (MR) in Fed State
50 mg MR in fed state
PF-06865571 400 mg MR in Fed State
400 mg MR in fed state
PF-06865571 400 mg MR in Fasted State
400 mg MR in fasted state
Brussels Clinical Research Unit, Brussels
Lead Sponsor
Pfizer
INDUSTRY